[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Tazi EM, Lalya I, Tazi MF, Ahellal Y, M'rabti H, Errihani H: Transitional cell carcinoma of the ovary: a rare case and review of literature. World J Surg Oncol; 2010;8:98
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal computed tomography showed a pelvic mass.
  • A staging operation with total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy and pelvic lymph node dissection was performed.
  • The patient underwent 3 cycles of chemotherapy: carboplatin and paclitaxel.
  • Surgical resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other types of ovarian cancers.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Hysterectomy / methods. Ovarian Neoplasms / diagnosis. Ovariectomy / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Staging. Pelvis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Int J Gynecol Pathol. 1987;6(1):29-39 [3570630.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):457-65 [2321577.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):195-9 [15790458.001]
  • [Cites] Am J Obstet Gynecol. 1993 Apr;168(4):1178-85; discussion 1185-7 [8475964.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):211-5 [7590475.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1995 Nov;30(11):658-61 [8745489.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jul;177(1):120-5 [9240594.001]
  • [Cites] Arch Pathol Lab Med. 2005 Feb;129(2):194-9 [15679420.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1995 Mar;30(3):153-6 [7796648.001]
  • (PMID = 21073751.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2996384
  •  go-up   go-down


2. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • Lymph node dissection was performed with an ultrasonic surgical knife.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


3. Tadokoro M, Masuda H, Fujii Y, Kobayashi T, Kageyama Y, Kihara K: Late relapse of stage I testicular seminoma metastatic to just a para-ureteropelvic region. Int J Urol; 2004 Nov;11(11):1044-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography scans of the abdomen showed a bulky tumor around the ureteropelvic region without para-aortic lymph node enlargement, but did not show a clear distinction between a recurrence of the testicular tumor and an invasive ureteral tumor.
  • After the patient underwent two cycles of chemotherapy with cisplatin and etoposide, the tumor mass decreased by approximately 60% and beta-hCG levels returned to normal.
  • We then performed a resection of the residual tumor involving the upper ureter and left kidney and a retroperitoneal lymph node dissection under a clinical diagnosis of recurrence of the testicular tumor.
  • [MeSH-major] Kidney Pelvis / pathology. Neoplasm Recurrence, Local / pathology. Seminoma / pathology. Testicular Neoplasms / pathology. Ureteral Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Hydronephrosis / etiology. Male

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509217.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Mohile SG, Schleicher L, Petrylak DP: Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol; 2008 Jan;5(1):55-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal carcinoma in an elderly woman.
  • No adjuvant therapy was administered.
  • INVESTIGATIONS: Physical examination, pelvic and complete lymph-node examination, laboratory tests, urine analysis, CT scan of the abdomen and pelvis, chest X-ray, bone scan, cystoscopy, histologic examination of tumor morphology, and MRI of the abdomen and pelvis.
  • DIAGNOSIS: Metastatic urachal adenocarcinoma.
  • MANAGEMENT: Surgical excision combined with cystectomy and pelvic lympadenectomy, chemotherapy with 5-fluorouracil, leucovorin, and irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / secondary. Cystectomy. Lymph Node Excision. Pelvic Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097457.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


5. Preis E, Jakse G: [The significance of inguinal lymphadenectomy in carcinoma of the penis]. Urologe A; 2006 Sep;45 Suppl 4:176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of inguinal lymph node metastases from squamous cell carcinoma of the penis depends on local tumor extension, tumor grade, and vascular invasion.
  • Whilst imaging techniques and fine needle biopsy can detect metastases to the inguinal nodes, resection of the superficial inguinal nodes remains the procedure of choice for diagnosis.
  • The risk profile defined in the guidelines of the EAU is used to decide whether modified inguinal lymphadenectomy is indicated in the case of nonpalpable lymph nodes.
  • Resection of the sentinel lymph node marked by (99)Tc and dye has not yet been adequately evaluated as an alternative to be accepted as the standard method.When the superficial inguinal lymph nodes are found to harbor metastases the next step is a radical bilateral inguinal lymphadenectomy.
  • When metastases are found in two lymph nodes or extranodal tumor growth is observed, or imaging techniques reveal enlarged nodes in the pelvis the lymphadenectomy is extended to the pelvic nodes.
  • Chemotherapy and radiotherapy and the two combined have not been tested for efficacy, but are used individually before and after surgery, depending on the local tumor extent.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision / methods. Penile Neoplasms / surgery
  • [MeSH-minor] Germany. Humans. Inguinal Canal. Lymphatic Metastasis / pathology. Male. Neoplasm Invasiveness. Neoplasm Staging. Penis / pathology. Postoperative Complications / etiology. Practice Guidelines as Topic. Prognosis. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Surg Oncol. 1990;6(4):241-2 [2389105.001]
  • [Cites] J Urol. 1987 May;137(5):880-2 [3573181.001]
  • [Cites] J Urol. 1986 Jul;136(1):38-41 [3712610.001]
  • [Cites] Eur Urol. 2005 May;47(5):601-6; discussion 606 [15826750.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):236-44; discussion 244-5 [15271324.001]
  • [Cites] J Urol. 1995 Dec;154(6):1999-2003 [7500444.001]
  • [Cites] J Urol. 1994 May;151(5):1239-43 [8158767.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] J Urol. 2004 Aug;172(2):494-7 [15247712.001]
  • [Cites] Br J Urol. 1994 Nov;74(5):646-51 [7530129.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] Int Urol Nephrol. 2002;34(2):245-50 [12775105.001]
  • [Cites] J Urol. 2003 Sep;170(3):783-6 [12913697.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] Acta Chir Scand. 1958 May 23;115(1-2):25-45 [13558905.001]
  • [Cites] J Urol. 1998 Nov;160(5):1770-4 [9783949.001]
  • [Cites] Eur Urol. 1994;26(2):123-8 [7957466.001]
  • [Cites] Cancer. 1955 Mar-Apr;8(2):371-8 [14352176.001]
  • [Cites] BJU Int. 2006 Jul;98(1):70-3 [16831146.001]
  • [Cites] J Urol. 2005 Sep;174(3):923-7; discussion 927 [16093989.001]
  • [Cites] Eur Urol. 1997;32(1):5-15 [9266225.001]
  • [Cites] BJU Int. 2000 Oct;86(6):690-3 [11069378.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):453-7 [9523669.001]
  • [Cites] J Urol. 2001 May;165(5):1633-4 [11342941.001]
  • [Cites] Br J Urol. 1965 Apr;37:211-22 [14282085.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1225-8 [16686716.001]
  • [Cites] J Urol. 2002 Apr;167(4):1638-42 [11912379.001]
  • [Cites] J Urol. 2003 Apr;169(4):1349-52 [12629358.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):267-76 [1574817.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Onkologie. 2005 Mar;28(3):135-8 [15772463.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Eur Urol. 2002 Sep;42(3):199-203 [12234502.001]
  • (PMID = 16933120.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


6. Ruvalcaba-Limón E, Cantú-de-León D, León-Rodríguez E, Cortés-Esteban P, Serrano-Olvera A, Morales-Vásquez F, Sosa-Sánchez R, Poveda-Velasco A, Crismatt-Zapata A, Santillán-Gómez A, Aguilar-Jiménez C, Alanís-López P, Alfaro-Ramírez P, Alvarez-Avitia MA, Aranda-Flores CE, Arias-Ceballos JH, Arrieta-Rodríguez O, Barragán-Curiel E, Botello-Hernández D, Brom-Valladares R, Cabrera-Galeana PA, Cantón-Romero JC, Capdeville-García D, Cárdenas-Sánchez J, Castorena-Roji G, Cepeda-López FR, Cervantes-Sánchez G, Cetina-Pérez Lde C, Coronel-Martínez JA, Cortés-Cárdenas SA, Cruz-López JC, de la Garza-Salazar JG, Díaz-Romero C, Dueñas-González A, Valle-Solís AE, Escudero-de los Ríos P, Flores-Alvarez E, García-Matus R, Gerson-Cwilich R, González-Enciso A, González-de-León C, Guevara-Torres AG, Herbert-Núñez GS, Hernández-Hernández C, Hernández-Hernández DM, Isla-Ortiz D, Jesús-Sandoval R, Jiménez-Cervantes C, Kuri-Exsome R, López-Obispo JL, Maffuz-Aziz A, Martínez-Barrera LM, Medina-Castro JM, Montalvo-Esquivel G, Mora-Aguilar VH, Morales-Palomares MA, Morán-Mendoza A, Morgan-Villela G, Mota-García A, Muñoz-González DE, Murillo-Cruz DA, Novoa-Vargas A, Ochoa-Carrillo FJ, Oñate-Ocaña LF, Ortega-Rojo A, Palacios-Martínez AG, Palomeque-López A, Pérez-Montiel MD, Quijano-Castro F, Rivera-Rivera S, Rivera-Rubí LM, Robles-Flores JU, Rodríguez-Trejo A, Salas-Gonzáles E, Silva JA, Solorza-Luna G, Souto-del-Bosque R, Tirado-Gómez LL, Torrescano-González S, Torres-Lobatón A, Trejo-Durán E, Villavicencio-Valencia V, Gallardo-Rincón D, Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México: [The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México]. Rev Invest Clin; 2010 Nov-Dec;62(6):583, 585-605
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México].
  • [Transliterated title] Primer consenso Mexicano de cancer de endometrio.
  • GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm.
  • RESULTS: Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II).
  • Diagnosis is made by histerescopy-guided biopsy.
  • Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy.
  • Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy.
  • Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence.
  • This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnostic Imaging. Estrogen Antagonists / adverse effects. Estrogen Replacement Therapy / adverse effects. Estrogens / adverse effects. Evidence-Based Medicine. Female. Humans. Hysterectomy / methods. Laparoscopy. Lymph Node Excision. Mass Screening. Mexico. Neoplasm Staging / methods. Radiotherapy, Adjuvant. Risk Factors. Salvage Therapy. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21416918.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Antagonists; 0 / Estrogens; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


7. Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B: Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):208-16
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
  • The majority of patients with clinical Stage I UPSC are found to have extrauterine disease at the time of surgery.
  • Surgical treatment as the sole therapy for patients with Stage I-IV UPSC is unacceptable because of high recurrence rates.
  • Chemotherapy, radiotherapy, or both have been added after surgery in an attempt to improve survival.
  • However, the survival benefit to patients from such multimodality therapy remains uncertain.
  • This study analyzes the patterns of failure in patients with FIGO Stages I-IV UPSC treated by multimodality therapy.
  • METHODS AND MATERIALS: Forty-two women with FIGO Stages I-IV UPSC who were treated by multimodality therapy were analyzed retrospectively between 1988 and 1998.
  • Data were obtained from tumor registry, hospital, and radiotherapy chart reviews, operative notes, pathology, and chemotherapy flow sheets.
  • All the patients underwent staging laparotomy, peritoneal cytology, total abdominal hysterectomy and salpingo oophorectomy, pelvic and para-aortic lymph node sampling, omentectomy, and cytoreductive surgery, when indicated followed by radiotherapy and/or chemotherapy.
  • Therapy consisted of external beam radiation therapy in 11 patients (26%), systemic chemotherapy in 20 (48%), and both radiotherapy and chemotherapy in 11 (26%).
  • The treatments were not assigned in a randomized fashion.
  • The dose of external beam radiation therapy ranged from 45-50.40 Gy (median 45).
  • Of the 31 patients (74%) who received chemotherapy, 18 received single-agent (58%), whereas 13 received multiagent chemotherapy (42%).
  • Twenty-nine patients (69%) had suffered recurrence at the time of last follow-up.
  • The majority of the patients (19/29) recurred in the abdomen, vagina, or pelvis (66%).
  • Twenty-five patients (60%) had died at the time of reporting; the observed survival rate at 2 years and 5 years was 52% and 43%, respectively.
  • CONCLUSIONS: Our data suggest that, after multimodality therapy of FIGO Stage I-IV UPSC, most patients developed abdominopelvic (locoregional) failure, and the great majority of the failures occurred in the abdomen, vagina, and pelvis (66%).
  • Distant failure alone occurred in 17% of the patients.We propose that future studies should combine whole abdominal radiotherapy (WART) with pelvic and vaginal boosts, in addition to chemotherapy for FIGO Stage I-IV UPSC, especially in patients with minimal residual disease, to attempt to improve the dismal prognosis of patients with UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Neoplasm Recurrence, Local / diagnosis. Uterine Neoplasms / mortality. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging / methods. Paclitaxel / administration & dosage. Retrospective Studies. Shiga Toxins / administration & dosage. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909235.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Shiga Toxins; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Marsden DE, Friedlander M, Hacker NF: Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol; 2000 Jul-Aug;19(1):11-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial carcinoma of the ovary is the most lethal of gynaecological malignancies and it affects about one in 70 women in developed countries.
  • Over 75% of women with the disease have tumour spread beyond the pelvis at the time of diagnosis, and their treatment requires the appropriate use of surgery and chemotherapy.
  • The strategies used in the treatment of ovarian cancer are constantly evolving.
  • An overview of current treatment regimens and their evolution is provided, with particular emphasis on the interdependence of surgery and chemotherapy in the optimal management of the disease.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Female. Humans. Laparotomy. Lymph Node Excision. Neoplasm Recurrence, Local. Neoplasm Staging. Platinum Compounds / therapeutic use. Reoperation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10883019.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Platinum Compounds
  • [Number-of-references] 127
  •  go-up   go-down


9. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of Urology: [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma]. Actas Urol Esp; 2010 Jan;34(1):51-62
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Actualización de las Guías Clínicas de la Asociación Europea de Urología sobre el carcinoma vesical músculo-invasivo y metastásico.
  • CONTEXT: New data regarding diagnosis and treatment of muscle-invasive and metastatic bladder cancer (MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) guidelines for MiM-BC.
  • EVIDENCE ACQUISITION: A comprehensive workup of the literature obtained from Medline, the Cochrane central register of systematic reviews, and reference lists in publications and review articles was developed and screened by a group of urologists, oncologists, and radiologist appointed by the EAU Guideline Committee.
  • EVIDENCE SYNTHESIS: The diagnosis of muscle-invasive bladder cancer (BCa) is made by transurethral resection (TUR) and following histopathologic evaluation.
  • Patients with confirmed muscle-invasive BCa should be staged by computed tomography (CT) scans of the chest, abdomen, and pelvis, if available.
  • Adjuvant chemotherapy is currently only advised within clinical trials.
  • Radical cystectomy (RC) is the treatment of choice for both sexes, and lymph node dissection should be an integral part of cystectomy.
  • Multimodality bladder-preserving treatment in localised disease is currently regarded only as an alternative in selected, well-informed, and compliant patients for whom cystectomy is not considered for clinical or personal reasons.
  • c) functional deterioration at particular sites; and d) consideration of treatment of a recurrence.
  • In metastatic disease, the first-line treatment for patients fit enough to sustain cisplatin is cisplatin-containing combination chemotherapy.
  • Presently, there is no standard second-line chemotherapy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cystectomy / methods. Diagnostic Imaging. Evidence-Based Medicine. Female. Humans. Lymph Node Excision. Male. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging / methods. Palliative Care. Risk Factors. Urinary Diversion / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223133.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Cormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L: Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl); 2010 May;19(3):302-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median interval between primary treatment of vulvar cancer and groin recurrence was 7 months.
  • Three patients refused any treatment, 3 received chemotherapy, 2 inguino-pelvic radiotherapy and 13 had resection of the groin recurrence.
  • After surgery seven patients received irradiation of the groin and pelvis, and three patients received chemotherapy.
  • One patient died following surgery; 19 patients died of disease with the median survival after diagnosis of inguinal recurrence of 9 months.
  • In univariate analysis, stage and grade at diagnosis, age and performance status at the recurrent disease, and the extent of residual tumour after resection of groin recurrence were predictors for survival.
  • Multi-modal treatment may result in a palliation of the disease, and a very limited number of patients have long-term survival.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Female. Groin. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832900.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol; 2009 Apr;55(4):815-25
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: New data regarding diagnosis and treatment of muscle-invasive and metastatic bladder cancer (MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) guidelines for MiM-BC.
  • EVIDENCE ACQUISITION: A comprehensive workup of the literature obtained from Medline, the Cochrane central register of systematic reviews, and reference lists in publications and review articles was developed and screened by a group of urologists, oncologists, and radiologist appointed by the EAU Guideline Committee.
  • EVIDENCE SYNTHESIS: The diagnosis of muscle-invasive bladder cancer (BCa) is made by transurethral resection (TUR) and following histopathologic evaluation.
  • Patients with confirmed muscle-invasive BCa should be staged by computed tomography (CT) scans of the chest, abdomen, and pelvis, if available.
  • Adjuvant chemotherapy is currently only advised within clinical trials.
  • Radical cystectomy (RC) is the treatment of choice for both sexes, and lymph node dissection should be an integral part of cystectomy.
  • Multimodality bladder-preserving treatment in localised disease is currently regarded only as an alternative in selected, well-informed, and compliant patients for whom cystectomy is not considered for clinical or personal reasons.
  • An appropriate schedule for disease monitoring should be based on (1) natural timing of recurrence, (2) probability of disease recurrence, (3) functional deterioration at particular sites, and (4) consideration of treatment of a recurrence.
  • In metastatic disease, the first-line treatment for patients fit enough to sustain cisplatin is cisplatin-containing combination chemotherapy.
  • Presently, there is no standard second-line chemotherapy.
  • [MeSH-major] Practice Guidelines as Topic. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157687.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 93
  •  go-up   go-down


12. Liu J, Li Y, Li S, Wang D, Hu T, Meng Y, Ma D, Cai H, Wang Z, Xiong C, Zhang H: Clinicopathological features and prognosis of small cell carcinoma of the cervix. J Huazhong Univ Sci Technolog Med Sci; 2010 Oct;30(5):626-30
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the clinicopathological features, diagnosis, treatment and prognosis of the condition were examined.
  • On the basis of their stages of condition, one subject with stage III b underwent chemotherapy, and one with stage Ib2 received extensive hysterectomy plus pelvic lymphadenectomy, while the other 5 cases were treated by extensive hysterectomy and pelvic lymphadenectomy in combination with pre- and/or post-operative adjuvant chemotherapy and radiotherapy.
  • It is concluded that SCCC is an aggressive tumor with propensity for early pelvis lymph node metastases.
  • Early-stage patients should be treated by extensive hysterectomy and pelvic lymphadenectomy in combination with pre- and/or post-operative adjuvant chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy / methods. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):27-33 [15047210.001]
  • [Cites] Int J Oncol. 1999 Nov;15(5):927-34 [10536175.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):28-32 [1845923.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3495-501 [12972526.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):672-7 [8299089.001]
  • [Cites] Int J Gynecol Pathol. 2004 Oct;23(4):366-72 [15381906.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):1-2 [9889021.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):712-8 [9708935.001]
  • [Cites] Int J Gynecol Pathol. 2005 Apr;24(2):113-7 [15782066.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):568-74 [12548598.001]
  • [Cites] Jpn J Clin Oncol. 1991 Aug;21(4):293-8 [1658416.001]
  • [Cites] Cancer. 1977 Nov;40(5):2243-9 [922663.001]
  • [Cites] Hum Pathol. 1999 Aug;30(8):906-10 [10452502.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(1):51-70 [6145674.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1489-93 [8608533.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):295-300 [15823115.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):427-31 [8641627.001]
  • (PMID = 21063846.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


13. Wu YC, Huang SL, Chuang CK, Jung SM, Lai CH: Successful salvage treatment of recurrent endometrial cancer with bulky central tumor and extensive lymph node metastasis. A case report. Eur J Gynaecol Oncol; 2004;25(6):739-41
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful salvage treatment of recurrent endometrial cancer with bulky central tumor and extensive lymph node metastasis. A case report.
  • A 55-year-old endometrial adenocarcinoma patient with bulky central recurrences and pelvic and inguinal lymph node metastases underwent laparotomy and paraaortic, pelvic and inguinal lymphadenectomy followed by concurrent chemoradiation (with cisplatin) to the paraaortic and inguinal lymph nodes as well as the whole pelvis.
  • Neck and mediastinal lymph node metastasis emerged during treatment.
  • Neck-node radiation and epirubicin was added followed by paclitaxel and carboplatin.
  • Therefore, a multimodality approach with a combination of radical resection (even pelvic exenteration), radiotherapy and chemotherapy could be offered to well-selected patients with recurrent endometrial cancer despite out-of-field progression during therapy and in-field local failure to initial salvage treatment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged. Salvage Therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15597856.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Petru E, Pasterk C, Reich O, Obermair A, Winter R, Breitenecker G: Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Arch Gynecol Obstet; 2005 Apr;271(4):316-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients tend to develop distant metastasis early and thus are potential candidates for systemic therapy.
  • Eight patients underwent radical surgery, 7 of whom also received chemotherapy.
  • Five of 8 surgically treated patients had lymph node involvement (62%).
  • Of the 7 patients with small-CC of the cervix only one, who had FIGO stage IIB disease and positive pelvic nodes, survived long-term (86 months) with no evidence of disease.
  • She had received six courses of dose-intensive platinum chemotherapy after radical surgery.
  • All three patients with small-CC of the uterine corpus or vagina developed recurrence within the first year after diagnosis.
  • Of the 7 patients who received chemotherapy, 5 developed progressive or recurrent disease in the paraaortic region (n=2), peritoneum (n=1), liver (n=1), or pelvis (n=1).
  • The optimal treatment for these patients most probably including concurrent chemo-radiotherapy remains to be defined.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


15. Haie-Meder C, Mazeron R, Magné N: Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol; 2010 Sep;96(3):351-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers.
  • PET-CT plays an increasing role in the diagnosis and treatment of gynaecological cancers.
  • In cervix cancer, whilst MRI remains the best imaging technique for initial primary tumor staging, PET-CT has been showed to be a highly sensitive method to determine lymph node status, except in patients with early-stage cervical cancer where PET-CT cannot replace surgical exploration of pelvic lymph nodes.
  • In patients with advanced cervical cancer, PET-CT has the potential of showing lymph node metastasis not only within the pelvis, but also outside the pelvis, more particularly in the para-aortic area.
  • In endometrial cancer, the issues are different, as the recent decade has seen a therapeutic decrease in early-stage disease, especially in postoperative radiation therapy, whilst more advanced disease have been approached with more aggressive treatments, integrating chemotherapy and external beam radiotherapy.
  • Lymph node status is also an important issue and PET-Scan may replace lymph node surgical procedure particularly in obese patients.
  • [MeSH-major] Endometrial Neoplasms / radiotherapy. Positron-Emission Tomography / methods. Radiotherapy Planning, Computer-Assisted / methods. Tomography, X-Ray Computed / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Brachytherapy. Female. Humans. Lymphatic Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Society for Therapeutic Radiology and Oncology and European Association of Nuclear Medicine. Published by Elsevier Ireland Ltd.. All rights reserved.
  • (PMID = 20709417.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


16. Aketa A, Yamada G, Aketa K, Ohnishi T, Takahashi Y, Kudoh K, Tanaka S, Shiratori M, Takahashi H, Watanabe A, Satoh M, Abe S: [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2004 Feb;42(2):164-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological diagnosis was pleomorphic carcinoma, p-T4 N2 M0.
  • After the operation, we performed systemic chemotherapy, including cisplatin and irinotecanm with little effect (PD).
  • However, we performed left upper segmentectomy and lymph node dissection because of invasion of the aorta and the chest wall, and because of hypersegmentation of the left upper lobe.
  • Pathological diagnosis was pleomorphic carcinoma, p-T4 N0 M0.
  • After the operation, the mediastinum was subjected to radiation therapy.
  • However, a metastatic tumor was found in the pelvis after this radiation was given.
  • We performed systemic chemotherapy with substances including cisplatin, gemcitabine and vinorelbine, but with little effect (PD).
  • Both cases had rapidly growing neoplasms showing little sensitivity to chemotherapy or radiotherapy.
  • Pulmonary pleomorphic carcinoma is suggested to be type of lung cancer with a poor prognosis when the tumor is not resected in the early stages.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neoplasms, Multiple Primary
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Age Factors. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007917.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Southcott BM: Carcinoma of the endometrium. Drugs; 2001;61(10):1395-405
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence rises with age and is significantly increased when there is exposure to unopposed estrogen, including hormone replacement therapy (HRT).
  • Transvaginal ultrasound and pipelle or hysteroscopy endometrial biopsies are tending to replace the traditional dilation and curettage in establishing a diagnosis.
  • Prognostic factors include the histological grade, the depth of invasion of the myometrium, the presence or absence of lymph-vascular space invasion and involved regional nodes, tumour volume, and the presence or absence of involvement of the cervix.
  • The pelvis is a major anatomical site at risk of recurrence, and since cytotoxic chemotherapy and hormone therapies have limited effectiveness, radiotherapy is the adjuvant therapy of choice where adverse prognostic factors are present.
  • A move towards more radical surgery--the addition of lymphadenectomy with a total abdominal hysterectomy and bi-lateral salpingo oophorectomy, may modify the value of adjuvant therapy and has highlighted the need to demonstrate the exact place of post operative radiotherapy in the management of endometrial cancer.
  • Spread outside the pelvis to para-aortic nodes may still be salvaged with local irradiation, but systemic disease is incurable and treatment is largely palliative including consideration of local irradiation, hormone therapy or chemotherapy for symptomatic relief.
  • As reliable techniques for diagnosis are refined an even larger proportion of patients will be diagnosed with early disease.
  • This, together with the development of new cytotoxic agents and sophisticated radiotherapy techniques to reduce normal tissue morbidity, will require the establishment of further clinical trials to refine optimal management.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Hormone Replacement Therapy / adverse effects. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Salvage Therapy. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):12-6 [8008305.001]
  • [Cites] Obstet Gynecol. 1979 Jul;54(1):85-9 [450367.001]
  • [Cites] Gynecol Oncol. 1974 Aug;2(2-3):368-76 [4616883.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):94-8 [8721599.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):118-22 [10385562.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):570-6 [10027332.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):422-3 [10366471.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jul;23(7):1025-9 [3665988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):817-24 [8244810.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] J Am Podiatr Med Assoc. 1996 Jul;86(7):331-3 [8757485.001]
  • [Cites] Cancer. 1987 May 1;59(9):1665-9 [3828966.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):261-4 [10021312.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7 [10393721.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1381-3 [10325299.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Acta Obstet Gynecol Scand. 1986;65(3):247-55 [3739631.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):687-92 [6498067.001]
  • [Cites] Acta Oncol. 1990;29(2):203-9 [2185804.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(5):425-36 [8253106.001]
  • [Cites] Clin Radiol. 1985 Nov;36(6):619-23 [4064547.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(2):87-9 [10376419.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):407-11 [10366468.001]
  • [Cites] J Chronic Dis. 1987;40 Suppl 2:59S-69S [3667868.001]
  • [Cites] Br J Hosp Med. 1995 Sep 6-19;54(5):198-201 [8528525.001]
  • [Cites] Obstet Gynecol. 1981 Nov;58(5):590-5 [7301235.001]
  • [Cites] Histopathology. 1999 Jan;34(1):51-5 [9934584.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(2):156-9 [10376438.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(6):520-1 [8971533.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(4):252-4 [10473722.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(1):8-12 [10422671.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(3):125-35 [4068799.001]
  • [Cites] Eur J Gynaecol Oncol. 1997;18(6):492-4 [9443018.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):320-7 [9010105.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jul;157(1):35-40 [3605266.001]
  • [Cites] Am J Clin Nutr. 1987 Jan;45(1 Suppl):283-9 [3799518.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):20-3 [3799753.001]
  • [Cites] Strahlenther Onkol. 1991 Jul;167(7):381-6 [1858012.001]
  • [Cites] Maturitas. 1999 Mar 15;31(3):237-40 [10340283.001]
  • [Cites] Obstet Gynecol. 1991 Dec;78(6):1033-8 [1945203.001]
  • [Cites] Mater Med Pol. 1995 Jan-Mar;27(1):23-5 [8569272.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):475-9 [8615657.001]
  • [Cites] Surg Gynecol Obstet. 1971 May;132(5):855-60 [5555407.001]
  • [Cites] Surg Clin North Am. 1991 Oct;71(5):991-1004 [1925858.001]
  • [Cites] Curr Opin Obstet Gynecol. 1994 Feb;6(1):92-7 [8180358.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] JAMA. 1996 Feb 7;275(5):370-5 [8569016.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(3):140-5 [8814367.001]
  • (PMID = 11558829.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 57
  •  go-up   go-down


18. Xing PY, Shi YK, Feng FY, Qin Y, Liu P: [Clinical characteristics and treatment of desmoplastic small round cell tumor]. Zhonghua Zhong Liu Za Zhi; 2010 Feb;32(2):139-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment of desmoplastic small round cell tumor].
  • OBJECTIVE: To investigate the clinical characteristics and treatment of desmoplastic small round cell tumor.
  • RESULTS: The median age of all cases was 23 (1.5 - 66) years old at the time of diagnosis.
  • In 46 patients (86.8%), the primary tumor was located in the abdomen or pelvis.
  • Fifteen (28.3%) had positive lymph nodes or distant parenchymal metastases.
  • Thirty-four patients received chemotherapy and the 1- and 3-year survival rates were 60.1% and 35.2%, respectively, however, only 29.7% and 12.7% in patients without chemotherapy (P = 0.0396).
  • Chemotherapy and radiotherapy correlate with improved patient outcome.
  • Multimodal therapy may improve the survival in patients with DSRCT.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / therapy. Desmoplastic Small Round Cell Tumor / pathology. Desmoplastic Small Round Cell Tumor / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Radiotherapy, Conformal. Surgical Procedures, Operative. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403246.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; IVAD protocol
  •  go-up   go-down


19. Bristow RE, Asrari F, Trimble EL, Montz FJ: Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol; 2001 May;81(2):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients diagnosed with FIGO Stage I-III UPSC undergoing ESS (vertical incision, peritoneal cytology, TAH/BSO, omental biopsy, lymph node sampling, peritoneal biopsy) between 1/1/89 and 12/31/98 were identified retrospectively from the tumor registry database.
  • The median age at diagnosis was 66 years.
  • Adjuvant radiation therapy (RT) was administered to 6/18 patients with Stage I/II disease and 5/8 patients with Stage III disease.
  • Platinum-based chemotherapy was administered to 5 patients with Stage III disease.
  • All recurrences of Stage I/II disease were located within the pelvis (16.7%).
  • The median follow-up time for surviving patients was 39.0 months (mean = 45.0 months).
  • The additional information provided by ESS facilitates the selection of adjuvant therapy.
  • For these patients, administration of adjuvant chemotherapy should be considered in addition to directed RT.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11330963.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, Minsky BD, Paty PB, Weiser MR, Temple LK, Wong WD, Larson SM, Guillem JG: Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol; 2008 Mar;15(3):704-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation.
  • Choice of optimal treatment--neoadjuvant chemoradiation versus systemic chemotherapy alone--depends on accurate assessment of distant disease.
  • We prospectively evaluated the ability of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) to detect distant disease in patients with locally advanced rectal cancer who were otherwise eligible for combined modality therapy (CMT).
  • Sites other than the rectum, mesorectum, or the area along the inferior mesenteric artery were considered distant and were divided into nine groups: neck, lung, mediastinal lymph node (LN), abdomen, liver, colon, pelvis, peripheral LN, and soft tissue.
  • Confirmation was based on tissue diagnosis, surgical exploration, and subsequent imaging.
  • Greatest accuracy was demonstrated in detection of liver (accuracy = 99.9%, sensitivity = 100%, specificity = 98.8%) and lung (accuracy = 99.9%, sensitivity = 80%, specificity = 100%) disease; PET detected 11/12 confirmed malignant sites in liver and lung.
  • All 10 were correctly staged by pre-CMT PET; abdominopelvic computed tomography (CT) scans accurately detected nine of them.
  • PET may play a significant role in defining extent of distant disease in selected cases, thus impacting the choice of neoadjuvant therapy.
  • [MeSH-major] Neoplasms, Multiple Primary / radionuclide imaging. Positron-Emission Tomography. Rectal Neoplasms / radionuclide imaging. Rectal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies. Single-Blind Method

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2008 Apr;15(4):1265. Leibold, Tobias [added]
  • (PMID = 17882490.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01 82534-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


21. Kirshtein B, Meirovitz M, Okon E, Piura B: Sister Mary Joseph's nodule as the first presenting sign of primary fallopian tube adenocarcinoma. J Minim Invasive Gynecol; 2006 May-Jun;13(3):234-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because frozen section examination revealed fallopian tube carcinoma, the procedure was continued with laparotomy including total abdominal hysterectomy, omentectomy, and pelvic lymph node sampling.
  • Final diagnosis was stage IIIB fallopian tube carcinoma.
  • The patient received postoperative adjuvant chemotherapy with single-agent carboplatin and has remained alive and with no evidence of disease.
  • It is concluded that in cases of Sister Mary Joseph's nodule, laparoscopy can be a useful tool in the search of the primary tumor in the abdomen and/or pelvis.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Adenocarcinoma / diagnosis. Fallopian Tube Neoplasms / diagnosis. Umbilicus
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Laparoscopy. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698532.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


22. Remzi FH, Kirat HT, Geisler DP: Laparoscopic single-port colectomy for sigmoid cancer. Tech Coloproctol; 2010 Sep;14(3):253-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Laparoscopic single-port sigmoid colectomy through a 3-cm umbilical incision was performed on a patient with a diagnosis of sigmoid cancer.
  • RESULTS: The total operative time was 198 min.
  • Examination of pathological specimen showed a specimen containing a circumferential lesion measuring 5 cm x 2.5 cm x 2.5 cm with adequate surgical margins (10 and 5.5 cm), and no regional lymph node metastases in 14 lymph nodes collected.
  • Patient did not receive adjuvant chemotherapy after surgery.
  • Colonoscopy performed 1 year after surgery showed no neoplasm or polyp identified.
  • Abdomen and pelvis CT also found no evidence of recurrence or metastatic disease.
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Length of Stay. Middle Aged. Neoplasm Staging. Pain, Postoperative. Sigmoidoscopy / methods. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2009 Apr;249(4):596-601 [19300230.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2002 May;16(5):833-5 [11997832.001]
  • [Cites] Arch Surg. 2007 Sep;142(9):823-6; discussion 826-7 [17875836.001]
  • [Cites] Eur J Surg. 1999 Jan;165(1):29-34 [10069631.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Aug;9(4):361-4 [10488834.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):77-81 [19106679.001]
  • [Cites] BJU Int. 2008 Jan;101(1):83-8 [18086101.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):558-66 [19404053.001]
  • [Cites] Surg Endosc. 2003 May;17(5):828-30 [12582763.001]
  • [Cites] Urology. 2008 Jan;71(1):3-6 [18242353.001]
  • [Cites] Endoscopy. 2007 Oct;39(10):913-5 [17968809.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • (PMID = 19953288.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Subramanian VS, Gilligan T, Klein EA: A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. Nat Clin Pract Urol; 2008 Apr;5(4):220-3
Genetic Alliance. consumer health - Testicular cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A scrotal ultrasound scan showed a right testicular mass, suspicious for neoplasm.
  • He opted to remain under surveillance rather than undergo primary chemotherapy or retroperitoneal lymph node dissection for his clinical stage I disease.
  • Serologic relapse at 4 months after orchiectomy was successfully treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy.
  • INVESTIGATIONS: Surveillance comprised regular clinic visits, measurement of serum levels of alpha-fetoprotein, human chorionic gonadotropin and lactate dehydrogenase, chest X-ray and CT of the abdomen and pelvis.
  • DIAGNOSIS: A 1.7 cm nodule anterior to the right psoas muscle suspicious for metastatic disease that was seen on CT 16 months after orchiectomy was pathologically confirmed as recurrent mature teratoma in the spermatic cord.
  • Additionally, one of eleven interaortocaval lymph nodes showed evidence of teratoma.
  • MANAGEMENT: Bilateral nerve-sparing retroperitoneal lymph node dissection with complete excision of the right spermatic cord was performed.
  • [MeSH-major] Genital Neoplasms, Male / therapy. Neoplasms, Germ Cell and Embryonal / surgery. Spermatic Cord / pathology. Teratoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Disease Management. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / therapy. Orchiectomy. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268549.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  •  go-up   go-down


24. Momoi H, Wada Y, Sarumaru S, Tamaki N, Gomi T, Kanaya S, Katayama T, Ootoshi M, Fukumoto M: Primary osteosarcoma of the breast. Breast Cancer; 2004;11(4):396-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary osteosarcoma of the breast, which is a rare histological type of all breast tumors.
  • There were small bone metastases to the pelvis and scapula on bone radionuclide scan, but no other metastasis was observed with subsequent investigations.
  • Modified radical mastectomy including axillary lymph node dissection was performed.
  • Histologically, the excised tumor was consistent with extraskeletal osteosarcoma of the breast accompanied by lymph node metastses.
  • In spite of adjuvant chemotherapy, the patient suffered a local recurrence four months later and died of aggressive multiple metastases 7 months after surgery.
  • [MeSH-major] Bone Neoplasms / diagnosis. Breast Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604996.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Halene S, Zieske A, Berliner N: Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol; 2006 Mar;3(3):165-8; quiz 169
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial symptoms resolved spontaneously without therapy, but fever recurred with associated arthralgias, myalgias, diffuse and worsening lymphadenopathy, splenomegaly, and bilateral pulmonary infiltrates.
  • INVESTIGATIONS: Physical examination, blood and urine cultures, MRI of the spine, echocardiogram, extensive serologies, serum and urine protein electrophoresis, immunofixation electrophoresis, bone-marrow aspiration and biopsy with flow cytometry, cytogenetics, and gene rearrangement studies, CT scan of the chest, abdomen and pelvis, whole-body PET, and lymph-node biopsy for histological examination, immunohistochemistry, and gene rearrangement studies.
  • DIAGNOSIS: Angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520806.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


26. Wu Q, Liu C, Lei L, Yan X, Wang B, Liu X, Yv L, Lv Y: Interdigitating dendritic cell sarcoma involving bone marrow in a liver transplant recipient. Transplant Proc; 2010 Jun;42(5):1963-6
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver transplantation is an effective treatment for patients with many kinds of liver diseases.
  • However, an increased risk of de novo malignancy has been reported in liver transplant recipients; immunosuppressive drugs have generally been identified as the primary culprit.
  • Interdigitating dendritic cell sarcoma (IDCS) is an exceedingly rare neoplasm arising from antigen-presenting cells of the immune system.
  • In this study, we have reported a case of IDCS with bone marrow involvement occurring in a 61-year-old female liver transplant recipient at 2 years after the procedure.
  • Physical examination revealed firm and painless nodes in both cervical and axillary fossae.
  • Computerized tomography of the chest, abdomen, and pelvis were negative.
  • To obtain a definite diagnosis, we performed an excisional lymph node biopsy and a bone marrow biopsy.
  • She responded to chemotherapy.
  • This case demonstrates the importance of cancer prevention and early detection for liver transplant recipients.
  • [MeSH-minor] Female. Hepatitis B / complications. Humans. Liver Cirrhosis / surgery. Liver Cirrhosis / virology. Lymph Nodes / pathology. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620556.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Mylonas I, Briese V, Vogt-Weber B, Friese K: Complete bilateral crossed ureteral duplication observed during a radical hysterectomy with pelvic lymphadenectomy for ovarian cancer. A case report. Arch Gynecol Obstet; 2003 Feb;267(4):250-1
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although bilateral ureteral duplication is an even rarer malformation than unilateral, it should be always considered as a differential diagnosis.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ureter / abnormalities
  • [MeSH-minor] Acetabulum. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Bone Neoplasms / ultrasonography. Fatal Outcome. Female. Femur. Humans. Hysterectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / surgery. Liver Neoplasms / ultrasonography. Lymph Node Excision. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pelvis / surgery. Sacrum

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12592431.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Ingen-Housz-Oro S, Bagot M: [Cutaneous lymphomas]. Rev Prat; 2009 Nov 20;59(9):1207-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous lymphomas are lymphoproliferations affecting skin only at the time of diagnosis.
  • There are two major types, B-cell lymphomas and T-cell lymphomas, which prognosis depends of histological subtype and staging evaluation.
  • In cutaneous B-cell lymphomas, there are two indolent subtypes (primary cutaneous marginal zone B-cell lymphoma and primary cutaneous follicle center lymphoma) and one more aggressive type (primary cutaneous diffuse large B-cell lymphoma, leg type).
  • Staging evaluation with CT-scan of chest, abdomen and pelvis, bone marrow examination if necessary and lymph node biopsy if palpable node over 1 or 1.5 cm diameter, is necessary for therapeutic decision.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / surgery. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiography. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Mycosis Fungoides / diagnosis. Mycosis Fungoides / radiography. Neoplasm Staging. Prognosis. Radiography, Abdominal. Radiography, Thoracic. Sezary Syndrome / diagnosis. Sezary Syndrome / pathology. Sezary Syndrome / radiography. Skin / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961071.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 16
  •  go-up   go-down


29. Borchers H, Jakse G: [Lymphadenectomy for penile cancer. Diagnostic and prognostic significance as well as therapeutic benefit]. Urologe A; 2005 Jun;44(6):657-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphadenectomy for penile cancer. Diagnostic and prognostic significance as well as therapeutic benefit].
  • Lymphadenectomy is an essential part of diagnosis and treatment of the squamous cell carcinoma of the penis.
  • The limits of lymphadenectomy are extended to the radical type of dissection when the frozen section indicates cancer.
  • Are more than 2 nodes positive the lymphnodes in the true pelvis have to be resected as well.
  • The immediate lymphadenectomy is superior to the delayed lymphadenectomy (palpable nodes during followup) in terms of local recurrence and survival.
  • In this situation it is reasonable to perform imaging studies of the pelvis and abdomen for adequate planning of the surgical approach.
  • Neoadjuvant chemotherapy is reasonable for patients with bulky nodes fixed to the skin or fascia because this improves respectability, freedom from local recurrence and increases survival.
  • Adjuvant chemo- and/or radio-therapy are reserved for extended disease or palliative situations.
  • [MeSH-major] Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Penile Neoplasms / pathology. Penile Neoplasms / surgery. Prostatectomy / methods. Risk Assessment / methods
  • [MeSH-minor] Clinical Trials as Topic. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Practice Guidelines as Topic. Practice Patterns, Physicians'. Preoperative Care / methods. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Urol. 2003 Nov;13(6):467-72 [14560140.001]
  • [Cites] J Urol. 1996 Nov;156(5):1637-42 [8863559.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] Int Urol Nephrol. 2002;34(2):245-50 [12775105.001]
  • [Cites] J Urol. 2002 Jul;168(1):76-80 [12050496.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1089-98 [9426328.001]
  • [Cites] J Urol. 2002 Jan;167(1):89-92; discussion 92-3 [11743282.001]
  • [Cites] Acta Oncol. 1988;27(6b):823-4 [2466471.001]
  • [Cites] J Urol. 1992 Mar;147(3):630-2 [1538445.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1638-9 [12356050.001]
  • [Cites] Urol Int. 1999;62(4):229-33 [10567890.001]
  • [Cites] Urologe A. 2003 Nov;42(11):1466-9 [14624345.001]
  • [Cites] J Urol. 2000 Jan;163(1):100-4 [10604324.001]
  • [Cites] BJU Int. 2000 Oct;86(6):690-3 [11069378.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] J Urol. 2001 May;165(5):1506-9 [11342906.001]
  • [Cites] BJU Int. 2003 Aug;92(3):248-50 [12887477.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] J Urol. 1994 May;151(5):1244-9 [7512656.001]
  • [Cites] J Urol. 2003 Apr;169(4):1349-52 [12629358.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Urology. 2001 Jul;58(1):65-8 [11445481.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):713-22 [9240637.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):525-31 [10668948.001]
  • (PMID = 15891865.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down






Advertisement